Ole Miss researchers study barriers to GLP-1 insurance coverage

Insurance companies frequently deny coverage for GLP-1 weight loss medications, despite clear medical data supporting their efficacy. A new study from the University of Mississippi clarifies the disconnect between clinical value and insurance budget impact.

Sujith Ramachandran, an associate professor of pharmacy administration, notes that cost-effective treatments are not automatically cost-saving for insurers. Because the population eligible for these drugs is significant, the total budget impact exceeds standard insurance thresholds. Even when medication is priced fairly relative to its health benefits, the sheer volume of potential users creates a fiscal hurdle for providers.

Researchers found little evidence that current medication use results in long-term savings for related conditions like heart disease or diabetes. This is largely because patients often stop treatment within a year due to cost or side effects, causing them to regain lost weight. To shift this dynamic, insurance providers would need to offer more than just the drug. Successful outcomes require a combination of medication, dietary guidance, and consistent physical activity programs.

Patients struggling with insurance denials often look to compounded versions of these drugs. However, experts urge caution regarding these alternatives. Compounded medications lack the rigorous oversight of FDA-approved options. Research indicates that some sources provide incorrect or unapproved ingredients, creating substantial safety risks. Experts advise patients to verify that any medication is FDA-approved and to maintain consistent communication with a physician throughout their treatment plan.